Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib on a Modified Augmented BFM Backbone in Newly Diagnosed T-ALL and T-LLy
NCT02112916Phase 3Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Oct 2014
- Primary completion
- Mar 2020
- Modality
- Small Molecules, Modified Peptides
- Countries
- 4
01
Overview
A Phase 3 trial of bortezomib in t-cell acute lymphoblastic leukemia (T-ALL), T cell lymphoblastic lymphoma (T-LBL), sponsored by National Cancer Institute. Started Oct 2014; status: active, not recruiting.
02
Drugs
bortezomib
03
Conditions
t-cell acute lymphoblastic leukemia (T-ALL)T cell lymphoblastic lymphoma (T-LBL)
Beyond the preview
Go deeper on NCT02112916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02112916.